KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash & Equivalents (2016 - 2026)

Boston Scientific's Cash & Equivalents history spans 18 years, with the latest figure at $1.5 billion for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 100.41% to $1.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 billion, a 100.41% increase, with the full-year FY2025 number at $2.0 billion, up 224.26% from a year prior.
  • Cash & Equivalents hit $1.5 billion in Q1 2026 for Boston Scientific, down from $2.0 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for BSX hit a ceiling of $2.9 billion in Q2 2024 and a floor of $276.0 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $1.1 billion across 5 years, with a median of $865.0 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 89.68% in 2022 and later soared 583.8% in 2024.
  • Tracing BSX's Cash & Equivalents over 5 years: stood at $928.0 million in 2022, then fell by 6.79% to $865.0 million in 2023, then fell by 29.94% to $606.0 million in 2024, then soared by 224.26% to $2.0 billion in 2025, then decreased by 26.06% to $1.5 billion in 2026.
  • Business Quant data shows Cash & Equivalents for BSX at $1.5 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.3 billion in Q3 2025.